A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Topotecan (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 01 Mar 2013 Actual end date Nov 2011 added as reported by ClinicalTrials.gov.
- 15 Oct 2008 Actual start date changed from Jul 2002 to Aug 2002 as reported by Clinicaltrials.gov
- 05 Jul 2007 Status changed from in progress to completed.